Prostate Cancer Program News

• Gabriel Eades, PhD 
  Mapping genetic interactions that contribute to lineage switching in t-NEPC
• Lore Hoes, PhD
  Interrogating in vivo hormone therapy sensitivity beyond mediators of resistance
• Steven Seyedin, MD and Jean-Philippe Coppé, PhD
  Elucidating the Kinome of Locally Recurrent Prostate Cancer after Definitive Radiotherapy
• Sha Zhu, MD, PhD
  Decoding STEAP1 Regulation and Therapeutic Targeting in Advanced Prostate Cancer

Research Pilot Award Recipients (Round 1)

• Jonathan Chou, MD, PhD
  Inhibition as a Therapeutic Strategy for CDK12-Mutated Prostate Cancer
• Erin Van Blarigan, ScD
  Eating Better Together: Developing a Dyadic Dietary Intervention for Prostate Cancer Patients and their Partners
• Meng Zhang, MSc, PhD
  Investigation of Microproteins as Novel Druggable Targets in Prostate Cancer

Research Pilot Award Recipients (Round 2)

• Anil Bidkar, PhD and Scott Bidlingmaier, PhD
  Actinium-225/MMAE Dual-Loaded Antibody Drug Conjugate for Prostate Cancer Targeted Therapy
• Peter Bruno, PhD
  Towards Identifying the Immunopeptidome of Prostate Cancer and its Role in Disease Progression
• Lisa Chesner, PhD
  Investigation of Wee1 inhibition for ATM-deficient prostate cancer
• Cornelia Ding, MD, PhD  and David Quigley, PhD
  The Molecular Pathologic Characterization of Double-Negative Metastatic Prostate Cancer
• Aidan Pace
  Effects of an Exercise Program on Markers of Inflammation and Insulinemia in Men on Active Surveillance for Prostate Cancer
• Kimberly Rickman, MD, PhD
  Defining prostate cancer tumor-immune system interactions in BRCA2 deficiency to identify therapeutic vulnerabilities
• Jiuling Yang, MD, PhD
  Unraveling the role of PVRL2 in tumor development and determining its therapeutic potential 
• Xiaolin Zhu, MD, PhD
  Investigating SSTR1 in Resistance to Androgen Receptor Signaling Inhibitors in Prostate Cancer

Research Pilot Award Recipients (Round 1)

• Ivan de Kouchkovsky, MD
  HP 13C MRI as an Early Response Biomarker to Androgen Deprivation Therapy Plus Abiraterone And Ipatasertib in Pelvic Node Positive Prostate Cancer
• Arian Lundberg, MSc, PhD
  Investigating the Association Between Microbiota Dysbiosis and Patient’s Survival in Advanced Prostate Cancer
• Woogwang Sim, PhD
  PTEN/TP53 Altered Prostate Cancer Has Unique Role for Tumor Associated Macrophages Upon Apalutamide Resistance

Research Pilot Award Recipients (Round 2)

• Arpita Desai, MD
  PSMA PET as a Longitudinal Biomarker in Patients Undergoing Intensified Intermittent ADT
• Nynikka Palmer, DrPH, MPH
  PACE Yourself: Optimizing Patient-Centered Communication for Prostate Cancer Care in the Safety-Net
• Samuel Washington III, MD, MAS
  Understanding Association Between Social Risk and Guideline Concordant Treatment for Clinically Localized Prostate Cancer
• Noah Younger, MD, PhD
  Characterizing cPRC1 as a Mediator of Enzalutamide Resistance in Advanced Prostate Cancer

• Rebecca Graff, ScD
  Metabolomic Disparities Between Black and White Men with Metastatic Prostate Cancer
• Haolong Li, PhD
  Investigating PTGES3 as a Novel Therapeutic Target in Advanced Prostate Cancer
• Osama Mohamad, MD, PhD
  Artificial Intelligence-Based Tools to Improve Decision Making for Patients with Prostate Cancer on Active Surveillance
• Duygu Kuzuoglu Oztur, PhD
  Elucidating the Roles of Different 5'UTRs of AR mRNA in Prostate Cancer
• Jingjing Li, PhD
  Single-Cell Analysis of Germline Mutations Conferring Population Disparities in Prostate Cancer
• Li Zhang, PhD
  Quantification of Adaptive Immune Response to Pembrolizumab for mCRPC Patients

• Nam Woo Cho, MD, PhD
  Systematic Dissection of Anti-Tumor Immunity Against Mismatch Repair-Deficient Prostate Cancer
• Crystal Langlais, MPH
  Development and Examination of Post-Diagnostic Lifestyle Scores for the Prevention of Prostate Cancer Progression
• Jingjing Li, PhD
  Deep Learning to Identify the Altered Chromatin Architecture from Large-Scale Prostate Cancer Genomes
• Ruhollah Moussavi-Baygi, PhD
  An in-silico Functional Genomics Approach for Determining Drivers of mCRPC in Individual Patients
• David Quigley, PhD
  Etiology and Therapeutic Vulnerabilities of Hypermethylated Metastatic Prostate Tumors

• Rohit Bose, MD, PhD
  Key Tumor Suppressors in Prostate Cancer Lacking ETS Fusions
• MinKyu Kim, PhD and Jonathan Chou, MD, PhD
  Mapping the Therapeutic Vulnerabilities of CDK12-Mutated Prostate Cancer
• Renuka Sriram, PhD
  Metabolic Characterization of Prostate Cancer Bone Metastatic Phenotypes Using Hyperpolarized 13C MRI -  Improved Assessment of Therapeutic Response

• Mekhail Anwar, MD, PhD
  A Microfabricated Imaging Platform for Intraoperative Detection of Microscopic Nodal and Margin Involvement in Prostate Cancer
• Robert Flavell, MD, PhD
  Boronated PSMA Neutron Capture Therapy for Treatment of Advanced Prostate Cancer
• Luke Gilbert, PhD
  Engineering an Expanded Therapeutic Window for Imaging and Treating Metastatic Prostate Cancer
• Hani Goodarzi, PhD
  Systematic Identification of Post-Transcriptional Regulatory Pathways that Drive Prostate Cancer
• Jim Wells, PhD
  Characterizing and Targeting the MYC Surface-ome in Advanced Prostate Cancer